Antiviral agent

Antiviral agent is thiazolidin-4-one with anti-hepatitis B activity

Samatasvir (ATOLIHZIXHZSBA-BTSKBWHGSA-N) is a pan-genotypic inhibitor of the HCV non-structural protein 5A.

2H-Pyrido[2',1':3,4]pyrazino[1,2-b]indazole-3-carboxylic acid, 6-(1, 1-Dimethylethyl)-6, 7-Dihydro-10 -(3-methoxypropoxy)-2-oxo-, (6R)- has antibacterial and antiviral activity and can be used to study Hepatitis B virus.

Antiviral Agent 51 (compound A) is a fucoidan and antiviral agent that inhibits Human alphaherpesvirus 1 and interacts with the RNA-dependent RNA polymerase (RdRp) of DENV-2, making it useful for studying dengue virus.

Antiviralagent 59 (compound 58) is a selective antiviral agent with drug-like properties, capable of inhibiting a broad spectrum of filoviruses. It demonstrates low off-target activity and inhibitory effects against replicative forms of Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV).

Antiviralagent 61 (compound Z40) serves as an effective antiviral agent with activity against Tomato Spotted Wilt Virus (TSWV), exhibiting an EC50 value of 252 µg/mL. It increases the RNA expression of Ndufb9, COX6B, 7.1.2.2, E, COX5B, Ndufs4, and SDHB, while reducing the expression of Ndufb7, Ndufa5, and G.

Antiviralagent 62 (Compound 16 h) is an orally active antiviral agent that inhibits the activity of HIV with an IC50 value of 8 nM against HIV (MJ4).

Antiviralagent 65 (compound 9) is an antiviral agent targeting the H1N1 influenza virus, with an EC50 of 7 μg/mL.

Antiviralagent 49 (compound 4q) is both an antiviral and antimicrobial agent, exhibiting activity against enterococci and staphylococci.

Antiviralagent 53 (Compound (S)-4v) is an antiviral agent capable of inhibiting the activity of Potato Virus Y (PVY), demonstrating remarkable curative and protective effects against PVY with EC50 values of 328.6 and 256.1 μg/mL, respectively. Antiviralagent 53 holds potential for the development of new agricultural pesticides.

Antiviralagent 54 (compound 33) is a broad-spectrum, orally active antiviral agent. It demonstrates antiviral activity against ZIKV, HCoV-OC43, and influenza A virus (IVA). Antiviralagent 54 also reduces ZIKV RNA and protein levels.

Antiviralagent 70 (Compound 12b) is an antiviral agent with exceptional binding affinity for neuraminidase (Neuraminidase). It exhibits potent antiviral activity against the H1N1 influenza virus, with an IC50 of 2.9 μM. This compound is applicable for research on influenza virus infections.

Antiviralagent 71 (Compound 26) is a potent antiviral agent exhibiting broad-spectrum activity against enteroviruses such as EV-D68, Echo-11, and HRV-14, with an EC50 ranging from 0.017 to 4.1 μM. Antiviralagent 71 is utilized in research related to non-polio enterovirus (NPEV) infections.

Antiviralagent 29 (one of the Example I) is a 2-mercapto-N-(5-amino-1,2,4-triazol-3-yl) benzenesulfonamide derivative that acts as an antiviral agent with activities against HIV, tumors, and arrhythmia.

Antiviralagent 78 (Compound 27) is an antiviral agent that exhibits inhibitory activity against various viruses. Its IC50 values are 11.22 μM for the 2019 novel coronavirus (2019-nCoV), 78.54 μM for the Ebola virus replicon, and 71.49 μM for the avian influenza virus A/Guangzhou/99. Antiviralagent 78 can be utilized in studies of viral infections.

Antiviralagent 77 (Compound 46) is a potent oral antiviral agent capable of crossing the blood-brain barrier. It demonstrates antiviral activity against CedV with an EC50 of 1.08 μM in rCedV-Luc reporter gene assays, as well as against NiV-M with an EC50 of 2.91 μM, NiV-B, and HeV.

Antiviral agent 5 is a crucial intermediate utilized in the development of antiviral agents that specifically target 3C and 3CL proteases, which includes the SARS-CoV-2 M pro enzyme.

Antiviral agent 18 (Compound 5) demonstrates significant antiviral activity against murine norovirus and holds potential for research in infectious and malignant diseases [1].

Antiviral agent 10 effectively inhibits the respiratory syncytial virus (RSV) [1], serving as a potent anti-viral compound.

Antiviral agent 14 is an antiviral compound that inhibits tobacco mosaic virus (TMV) with an EC50 of 135.5 μg/mL and cucumber mosaic virus (CMV) with an EC50 of 178.6 μg/mL.

Antiviral agent 15 (Compound 15f) is a Clofazimine derivative with antiviral activity, inhibiting the rabies virus (EC50: 1.45 μM) and pseudotyped SARS-CoV-2 (EC50: 14.6 μM).

Antiviral agent 19 (Compound 3) is a selective inhibitor of the Zika virus (EC50: 1.3 μM) with low cytotoxicity.

Antiviral agent 6 showed excellent anti-TSWV effects in vivo (EC50: 188 mg/L).

Antiviral agent 7 is a peptide-based coating that effectively eliminates viruses.